Personalized immune cells target advanced sarcoma in major trial
Disease control
Recruiting now
This study is testing a new personalized cell therapy called TBI-1301 for adults with advanced synovial sarcoma, a rare and aggressive cancer. The treatment involves collecting and modifying a patient's own immune cells to target a specific protein (NY-ESO-1) found on their tumor…
Phase: PHASE3 • Sponsor: Takara Bio Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC